Multiple Sclerosis
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Subtype terms (2)
More specific conditions that are subtypes of Multiple Sclerosis in the MeSH hierarchy.
- Multiple Sclerosis, Chronic Progressive
81 drugs (44 approved, 37 experimental)
- Multiple Sclerosis, Relapsing-Remitting
162 drugs (94 approved, 68 experimental)
Drugs by status
Approved for this indication (38)
- dantrolene
- corticotropin
- dexamethasone
- fingolimod
- mitoxantrone
- water
- triamcinolone
- dimethyl fumarate
- simvastatin
- baclofen
- peginterferon beta-1a
- siponimod
- ozanimod
- ponesimod
- natalizumab
- cannabidiol
- dalfampridine
- ocrelizumab
- betamethasone
- lincomycin
- alemtuzumab
- monomethyl fumarate
- ofatumumab
- interferon beta-1a
- mycophenolate
- cladribine
- interferon beta-1b
- diroximel
- pacritinib
- naltrexone
- +8 more
Phase 4 trials (37)
- cetirizine
- nabilone
- memantine
- keyhole limpet hemocyanin
- escitalopram
- montelukast
- tetanus toxoid
- brimonidine
- gadobutrol
- tetracaine
- mirabegron
- levetiracetam
- tetrahydrocannabinol
- fludeoxyglucose f-18
- diclofenac
- vitamin d3
- oxybutynin
- solifenacin
- bnt162b2
- diphtheria toxoid
- lubiprostone
- oxycodone
- oxygen
- mrna-1273
- calcium carbonate
- interferon alfa-1b
- suvorexant
- onabotulinumtoxinA
- lidocaine
- acetaminophen
- +7 more
Phase 3 trials (62)
- clemastine
- cranberry
- armodafinil
- dronabinol
- Vidofludimus
- orelabrutinib
- tolebrutinib
- vaccine against cd4 reactive t cells
- diphenhydramine
- estradiol
- arbaclofen
- propionic acid
- amantadine
- Nomegestrol acetate
- fish oil
- frexalimab
- l-epigallocatechin
- neurovax
- paroxetine
- prednisolone
- iobenguane sulfate i-131
- Honeybee venom
- ranitidine
- masitinib
- aciclovir
- Remibrutinib
- inactivated influenza vaccine
- immune globulin (human)
- hemopoietic stem cell
- cholestyramine
- +32 more
Phase 2 trials (142)
- methotrexate
- etoposide
- Rolipram
- autologous bone marrow derived mesenchymal cells
- carbidopa
- atorvastatin
- pirtobrutinib
- meningococcal (groups A, C, Y, W) tetanus toxoid conjugate vaccine
- bisacodyl
- kyv-101
- firategrast
- mrna-1195
- interferon alpha-2b
- gabapentin
- hydroxychloroquine
- caba-201
- idebenone
- famciclovir
- mitoquinone
- ursodeoxycholic acid
- acetazolamide
- bone marrow derived mesenchymal stem cells
- ly3541860
- umbilical cord mesenchymal stem cells
- itraconazole
- quetiapine
- ps13
- live hookworm larvae
- SAR443820
- isoxsuprine
- +112 more
Phase 1 trials (91)
- hydroxytyrosol
- tolerogenic fibroblasts
- gz402668
- ro7121932
- [zr-89]oxine-labeled leukocytes
- multivitamins
- vx15/2503
- allogenic placenta derived mesenchymal stem cells
- tak-988
- 18f-feppa
- d-mannose
- rd06-05
- pf-06342674
- liothyronine
- 123i clinde
- mangafodipir trisodium
- glibenclamide
- ims001
- gsk2018682
- loratadine
- 11c-bms-986196
- cs0777
- autologous adipose-derived mesenchymal stem cells
- ct-rd06
- bht-3009
- p-cd19cd20-allo1 cells
- iab22m2c
- [f-18]sdm-8
- urea
- autologous mesenchymal stem cell-derived neural progenitors
- +61 more
Other trials (26)
Organizations
Organization Involved with Phase 4 Indications (97)
- CogState Ltd.
- Endo Pharmaceuticals
- Ente Ospedaliero Cantonale
- University of Washington
- Mallinckrodt
- Medical College of Wisconsin
- University Hospital of North Norway
- Bayer
- University of Genoa
- Tel Aviv University
- Brown, Theodore R., M.D., MPH
- Stichting MS Research
- State University of New York
- Erasmus University Rotterdam
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Innovatiefonds Zorgverzekeraars
- University of North Carolina at Chapel Hill
- Louisiana State University
- Patient-Centered Outcomes Research Institute
- University of Haifa
- Merck Serono
- Holy Name Medical Center, Teaneck, NJ
- University of Rochester
- Cantonal Hospital of St. Gallen
- EvergreenHealth
- University of Colorado
- Georgia State University
- Social Security Mexican Institute
- Clinique Neuro-Outaouais
- St. Antonius Hospital, Nieuwegein
- +67 more
Organization Involved with Phase 3 Indications (211)
- University of Tromso
- Hospital of Central Denmark Region, Viborg, Denmark
- National Eye Institute (NEI)
- Policlinico Universitario Centro Sclerosi Multipla
- Vita-Salute University of Milano. Italy
- Phoenix Neurological Associates, LTD
- University of Western Ontario
- University of South Carolina
- Department of Education
- Byondis
- Helse Forde
- Northwestern University
- Government of France
- Metrolina Medical Research
- TG Therapeutics, Inc.
- Providence Health & Services
- Central Texas Neurology Consultants
- Telemark Hospital Trust
- Island Neurological Associates, PC
- Advanced Neurosciences Institute
- Universidad Autonoma de Madrid
- The Neurological Institute, PA
- Pennsylvania State University
- Alkermes
- Sheffield Hallam University
- Springfield Neurology Associates, LLC
- Oslo Metropolitan University
- Suncoast Neuroscience Associates, Inc.
- Norwegian University of Science and Technology
- University of Virginia
- +181 more
Organization Involved with Phase 2 Indications (168)
- Coherus BioSciences
- Immune Tolerance Network
- Medical Research Council
- Pontificia Universidad Catolica de Chile
- National Cancer Institute (NCI)
- University of Hull
- Albany Medical College
- Avigen
- Keele University
- University of Zurich
- University of Basel
- OvaMed GmbH
- Universidad Autonoma de Barcelona
- RemeGen
- University of Alberta
- Stony Brook University
- SocraMetrics GmbH
- German Federal Ministry of Education and Research
- MS Hub Medical Group
- University of Chile
- Danish Research Centre for Magnetic Resonance
- University of Louisville
- MorphoSys
- Southend University Hospital Foundation NHS Trust
- University of Warwick
- Royan Institute
- National Center of Neurology and Psychiatry, Japan
- Sutter East Bay Medical Foundation
- The Cleveland Clinic
- University of Pittsburgh
- +138 more
Organization Involved with Phase 1 Indications (52)
- University of Iowa
- Brain Health Alliance
- Hammersmith Medicines Research
- Revert ONLUS
- MedImmune
- University of Antwerp
- Molecular NeuroImaging
- Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.
- Anokion SA
- BfARM, Bonn
- Banner Life Sciences LLC
- University of Lausanne
- TZ Press, LLC
- Pinnaclife Inc.
- Artielle ImmunoTherapeutics
- Makati Medical Center
- Arrien Pharmaceuticals
- Abide Therapeutics
- IDT Australia Ltd.
- Fondazione Cellule Staminali
- Pfenex, Inc
- Daiichi Sankyo
- Pavlov First Saint Petersburg State Medical University
- BioPartners GmbH
- Repligen Corporation
- Aix-University of Marseille
- Centre for Probe Development and Commercialization
- University of Illinois at Chicago
- University of Bonn
- STRAGEN
- +22 more
Organization Involved with Other Experimental Indications (24)
- CarnoMed
- The Foundation of Lily Benthine Lund
- American University of Beirut
- Fonden for scleroseramte paa Fyn
- Hasselt University
- Orbis Medical Centre
- University of Athens
- iReportoire Inc
- The Lounkaer Foundation
- Region of Southern Denmark
- Imperial College London
- Duke University
- Mandell Center for Multiple Sclerosis
- Wake Forest University
- Tanner Center for MS
- Tanner Foundation for Multiple Sclerosis
- University of Novi Sad
- The Augustinus Foundation, Denmark.
- Saint Francis Hospital and Medical Center
- University of South Florida
- Cerecin
- Institute for Clinical Research
- Kessler Medical Rehabilitation Research and Education Corporation
- Sun Yat-Sen University